Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

1. www.nejm.org › doi › fullSecond-Line Switch to Dolutegravir for Treatment of HIV Infection

   www.nejm.org › doi › full

   21 Ιουν 2023 · Data to inform the switch from a ritonavir-boosted protease inhibitor (PI) to dolutegravir in patients living with human immunodeficiency virus (HIV) infection who do not have genotype...

   • Dolutegravir Plus Two Different Prodrugs of Tenofovir to Treat HIV

     New directions in the 2015 WHO Consolidated ARV Guidelines:...

2. www.aidsmap.com › news › mar-2024Islatravir plus lenacapavir could be the first once-weekly oral...

   www.aidsmap.com › news › mar-2024

   • Αποθηκευμένο αντίγραφο

   6 Μαρ 2024 · New & experimental HIV treatments Lenacapavir May Be Beneficial for Individuals Infected With HIV-2 Researchers evaluated the antiviral activity of lenacapavir against HIV-2 isolates and drug-resistant HIV-2 variants.

3. www.hiv.gov › blog › fda-approves-new-hiv-drug-for-adults-with-limited-treatmentFDA Approves New HIV Drug for Adults with Limited Treatment...

   www.hiv.gov › blog › fda-approves-new-hiv-drug-for-adults-with-limited-treatment

   • Αποθηκευμένο αντίγραφο

   4 Ιαν 2023 · [On December 22, 2022], the U.S. Food and Drug Administration approved Sunlenca (lenacapavir), a new type of antiretroviral medication for adult patients living with human immunodeficiency virus type 1 (HIV-1), whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety ...

4. www.npr.org › 2021/12/23 › 1067172062The FDA has approved a new drug in the fight against AIDS

   www.npr.org › 2021/12/23 › 1067172062

   23 Δεκ 2021 · The Food and Drug Administration has approved the first injectable medication for HIV prevention. Health advocates say it could be a game changer in protecting people against AIDS

5. www.thelancet.com › journals › lanhivPost-exposure prophylaxis to prevent HIV: new drugs, new...

   www.thelancet.com › journals › lanhiv

   9 Νοε 2023 · Several open-label studies have evaluated different regimens containing INSTIs in conjunction with nucleoside reverse transcriptase inhibitors for PEP. Raltegravir-based regimens have been generally well tolerated with mild side-effects, the most notable being musculoskeletal symptoms.

6. www.thelancet.com › journals › eclinmComparative efficacy, tolerability and safety of dolutegravir and...

   www.thelancet.com › journals › eclinm

   1 Ιουλ 2020 · In this review, the evidence for HIV-TB co-infected persons treated with DTG is based primarily on the findings of the INSPIRING trial, which compared twice-daily DTG 50 mg to once-daily EFV 600 mg.

7. pubmed.ncbi.nlm.nih.gov › 34742581Update and latest advances in antiretroviral therapy - PubMed

   pubmed.ncbi.nlm.nih.gov › 34742581

   In this review, we provide an overview on currently available anti-HIV drugs and the latest developments in antiretroviral therapy, focused on new antiretroviral agents acting on known and unexploited antiviral targets, prevention therapies aimed to improve available drug combinations, and research on new long-acting therapies, particularly ...